CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 82 enrolled
Drug / intervention
Bone Density Testother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07336693
NCT07336693N/ACompleted

Changes in Bone Mineral Density and the Impact of Therapeutic Approaches in Postmenopausal Patients With Rheumatoid Arthritis

Istanbul University - Cerrahpasa·observational·Posted Jan 13, 2026·Updated Jan 13, 2026

In Brief

An observational study evaluating Bone Density Test for Rheumatoid Arthritis (RA) and Osteoporosis. Completed, enrolled 82 participants across 1 site.

Detailed Summary

Rheumatoid arthritis is associated with systemic inflammation-mediated bone loss, leading to an increased risk of osteoporosis and fractures, particularly in postmenopausal patients. Although disease-modifying antirheumatic drugs may help mitigate bone loss, comparative longitudinal data on different treatment strategies remain limited. This study aimed to evaluate changes in bone mineral density over time and assess the impact of conventional synthetic and biologic DMARDs, together with anti-osteoporotic therapy, on bone health.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
2026
First PostedJan 13, 2026
Enrollment StartJun 1, 2025
Primary CompletionSep 1, 2025
Study CompletionDec 1, 2025
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6 months ago

Interventions

Bone Density Testother

BMD values were obtained from DXA scans performed at the lumbar spine (L1-L4), femoral neck, and total femur. All DXA measurements were conducted at the Department of Nuclear Medicine using the same device, a Hologic QDR 4500SL (S/N 45624, Bedford, MA), to ensure methodological consistency. Reference values were based on the NHANES III.